Re: Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial

Samir S. Taneja

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)656-658
Number of pages3
JournalJournal of Urology
Volume191
Issue number3
DOIs
StatePublished - 2014

ASJC Scopus subject areas

  • Urology

Cite this